Disclosed are compositions and methods for the treetment of disorders such as myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). The disclosed methods include administering to an individual in need of such treatment a composition that may include an IRAKI/4 inhibitor, In other aspects, the method may include administration of a BLC2 inhibitor.